Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice

Circulation

Volumn 113, Issue 1, 2006, Pages 81-89

  Mekontso Dessap, A ^a   Brouri, F ^b   Pascal, O ^a   Lechat, P ^b   Hanoun, N ^b   Lanfumey, L ^b   Seif, I ^c   Benhaiem Sigaux, N ^d   Kirsch, M ^d   Hamon, M ^b   Adnot, S ^a   Eddahibi, S ^a,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

Fibrosis; Heart diseases; Pathology; Serotonin; Valves

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; ANOREXIGENIC AGENT; FENFLURAMINE; IPRONIAZID; KETANSERIN; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PHENTERMINE; PROLINE; SEROTONIN; SEROTONIN TRANSPORTER; 5 HYDROXYINDOLEACETIC ACID; MESSENGER RNA; SEROTONIN 1B RECEPTOR; SLC6A4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOID; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; FIBROSING ALVEOLITIS; GENE INACTIVATION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; IN VIVO STUDY; LUNG BLOOD VESSEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTONIN RELEASE; SOUTHERN BLOTTING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE; VALVULAR HEART DISEASE; VASCULAR FIBROSIS; ANIMAL; BLOOD; CYTOLOGY; ECHOGRAPHY; FIBROBLAST; FIBROSIS; GENETICS; HEART MUSCLE; HUMAN; MALE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; FIBROBLASTS; FIBROSIS; HEART VALVE DISEASES; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; RECEPTOR, SEROTONIN, 5-HT1B; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33644865941     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.554667     Document Type: Article

References (28)

1. Ahlman H. Serotonin and carcinoid tumors. J Cardiovasc Pharmacol. 1985;7(suppl 7):S79-S85.
2. Alegret JM, Subirana MT, Marcuello E, Bayes-Genis A, Ferres P, Torner M. Tricuspid and pulmonary valve in a case of carcinoid syndrome. Rev Esp Cardiol. 1997;50:532-534.
3. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
4. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis. 1996;5:235-237.
5. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283:1703-1709.
6. Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, Solligård E, Fossmark R, Bakke I, Syversen I, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation. 2005;111:1517-1522.
7. Lesch KP, Wolozin BL, Estler HC, Murphy DL, Rieder P. Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm (Gen Sect). 1993;91:67-72.
8. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD. Antidepressant-and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1993;90:2542-2546.
9. Lee SL, Fanburg BL. Serotonin uptake by bovine pulmonary endothelial cells in culture, II: stimulation by hypoxia. Am J Physiol. 1986;250:C766-C770.
10. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141-1150.
11. Mast S, Gersing K, Anstrom K, Krishnan K, Califf R, Jollis J Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol. 2001;87: 989-993.
12. Eddahibi S, Hanoun N, Lanfumey L, Lesch K, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105:1555-1562.
13. Bengel D, Murphy D, Andrews A, Wichems C, Feltner D, Heils A, Mossner R, Westphal H, Lesch K. Altered brain serotonin homeostasis and locomotor insensitivity to 3.4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol. 1998;53:649-655.
14. Trillat AC, Malagie I, Bourin M, Jacquot C, Hen R, Gardier AM. Homozygous mice deficient in serotonin 5-HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors. C R Seances Soc Biol Fil. 1998;192:1139-1147.
15. Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: relationship with the mitogenic action of serotonin. Circ Res. 1999;84:329-336.
16. Fujiwara H, Onodera T, Tanaka M, Fujiwara T, Kawai C, Hamashima Y. The reliability of the tracing-method of fine cardiac fibrosis at a magnification of X10: preliminary study for quantitative analysis of fibrosis in large tissue sections of hearts with cardiomyopathy. Heart Vessels. 1985;1:182-184.
17. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083-1152.
18. Hamon M, Fattaccini C, Adrien J, Gallissot M, Martin P, Gozlan H. Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther. 1988;246:745-752.
19. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vodjdani G. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci U S A. 2003;100:13525-13530.
20. Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic β-adrenoceptor blockade. Br J Pharmacol. 2003;140:1434-1441.
21. Nebigil CG, Jaffre F, Messaddeq N, Hickel P, Monassier L, Launay JM, Maroteaux L. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation. 2003;107:3223-3229.
22. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci. 2003;21:417-424.
23. Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature. 1988;335:254-256.
24. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis. 2000;9:256-260.
25. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75-81.
26. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836-2841.
27. Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, Rosenzweig-Lipson S, McGonigle P, Levy RJ, Liang B. Serotonin mechanisms in heart valve disease, II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol. 2002;161:2209-2218.
28. Jian B, Xu J, Connolly J, Savani R, Narula N, Liang B, Levy R. Serotonin-induced up-regulation of transforming growth factor-β1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol. 2002;161:2111-2121.